Technology ID

Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES

Lead Inventor
Cowan, Kenneth (NCI)
Research Materials
Therapeutic Areas
Development Stages
Pre-clinical (in vivo)
Lead IC

Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.

Researchers at the National Cancer Institute (NCI) have derived an Adriamycin-resistant cell line, NCI/ADR-RES, from human ovarian cancer cells. The parental cell line is OVCAR-8, obtained from a high-grade ovarian serous adenocarcinoma. NCI/ADR-RES is resistant to Adriamycin and found to express high levels of the Multi-Drug Resistance 1 (MDR1) protein – also known as P-glycoprotein. The cell line was extensively characterized and proven useful in identifying compounds subject to multi-drug resistance. NCI/ADR-RES was deposited into the Division of Cancer Treatment and Diagnosis (DCTD) Developmental Therapeutics Program (DTP) Tumor Repository and added to the NCI-60 Human Tumor Cell Lines Screen, along with parental OVCAR-8. Molecular characterization data are publicly available on the DTP website.

NCI is seeking parties to non-exclusively license the ADR-RES cell line.

Competitive Advantages:

  • Extensively characterized and documented human ovarian adenocarcinoma cell line
  • Part of the NCI anti-cancer drug screen human cell line panel (NCI-60 Human Tumor Cell Lines Screen)
  • Molecular characterization data are publicly available


Commercial Applications:

  • Research tool to study the multi-drug resistance phenomenon in cancer
  • Research tool to study Adriamycin resistance in ovarian cancer
  • Research tool to study the overexpression of MDR1 (P-glycoprotein) in cancer
Licensing Contact:
Pollack, Michael